SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Description

Transforming growth factor receptor beta 2 (TGFBR2) encodes the TGF-β receptor protein, which is a transmembrane protein that forms a heterodimeric complex with other receptor proteins and binds TGF-β. This receptor/ligand complex phosphorylates proteins which regulate cell proliferation, cell cycle arrest, wound healing, and immunosuppression. Mutations in TGFBR2 have been linked with Marfan syndrome and the development of various types of tumors.

The TGFBR2 CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles ready to infect most types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNA) targeting human TGFBR2(Figure 1 and Table 2).

The DNA transduced by this lentivirus integrates randomly into the cellular genome to express both Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Knockdown efficiency is dependent on cell type.



Figure 1: Schematic of the lenti-vector used to generate the TGFBR2 CRISPR/Cas9 Lentivirus.

Gene Target:	sgRNA Sequence:
TGFBR2-1-F	ACAGTGATCACACTCCATGT
TGFBR2-2-F	TATCATGTCGTTATTAACTG
TGFBR2-3-F	GCAGAAGCTGAGTTCAACCT
TGFBR2-4-F	AAAGCGACCTTTCCCCACCA
TGFBR2-5-F	ACCTACAGGAGTACCTGACG

Table 1: List of sgRNA Sequences in the TGFBR2 CRISPR/Cas9 Lentivirus.

Application

- Transient knockdown of TGFBR2 in target cells
- Generation of a stable TGFBR2 knockout cell line following puromycin selection and limiting dilution

Formulation

The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS.

Titer

Two vials (500 µl x 2) of lentivirus at a titer ≥1 x 10^7 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.

Storage

Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

Biosafety

The lentiviruses are produced with the SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

Figures and Validation Data



Figure 2: Knockdown of TGFBR2 in Jurkat cells using TGFBR2 CRISPR/Cas9 Lentivirus.
Jurkat cells were transduced via spinoculation with 1 x 10^7 TU/well of TGFBR2 CRISPR/Cas9 lentivirus, corresponding to an MOI >5. 48 hours after transduction, cells were stained with TGFBR2 Recombinant Polyclonal antibody (ThermoFisher #710276), followed by a PE labeled anti-rabbit secondary (BioLegend #406421) and analyzed by flow cytometry. Non-transduced, parental Jurkat cells are shown in blue, and the transduced cells are shown in green.

Troubleshooting Guide

Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.

Notes

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.

Related Products

Products	*Catalog #*	*Size*
CTLA4 CRISPR/Cas9 Lentivirus (Non-Integrating)	78061	500 µl x 2
CTLA4 CRISPR/Cas9 Lentivirus (Integrating)	78054	500 µl x 2
TIGIT CRISPR/Cas9 Lentivirus (Non-Integrating)	78065	500 µl x 2
TIGIT CRISPR/Cas9 Lentivirus (Integrating)	78058	500 µl x 2
CD47 CRISPR/Cas9 Lentivirus (Non-Integrating)	78063	500 µl x 2
CD47 CRISPR/Cas9 Lentivirus (Integrating)	78056	500 µl x 2